Community Health (NYSE: CYH) CFO gets stock grants and covers taxes
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Community Health Systems EVP & CFO Jason K. Johnson reported multiple equity transactions. On March 1, 2026, 30,000 performance-based restricted shares vested at 100% of target for the 2023–2025 performance period and were converted into 30,000 shares of common stock.
He was also granted 180,000 new performance-based restricted shares and 90,000 stock options, all held directly, with vesting tied to multi-year performance and time-based schedules described in the footnotes, including periods through 2028. In addition, he received 90,000 restricted shares of common stock, with restrictions lapsing in one-third increments over three years.
To cover tax obligations related to these awards, 23,610 shares of common stock were disposed of at $3.46 per share, leaving Johnson with 268,439 shares of common stock held directly after the transactions.
Positive
- None.
Negative
- None.
Insider Trade Summary
30,000 shares exercised/converted
Mixed
14 txns
Insider
Johnson Jason K
Role
EVP & CFO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Performance Based Restricted | 30,000 | $0.00 | -- |
| Grant/Award | Performance Based Restricted | 180,000 | $0.00 | -- |
| Grant/Award | Stock Options (Right to Buy) | 90,000 | $0.00 | -- |
| Exercise | Common Stock | 30,000 | $0.00 | -- |
| Grant/Award | Common Stock | 90,000 | $0.00 | -- |
| Tax Withholding | Common Stock | 23,610 | $3.46 | $82K |
| holding | Performance Based Restricted | -- | -- | -- |
| holding | Performance Based Restricted | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
| holding | Stock Options (Right to Buy) | -- | -- | -- |
Holdings After Transaction:
Performance Based Restricted — 0 shares (Direct);
Stock Options (Right to Buy) — 90,000 shares (Direct);
Common Stock — 202,049 shares (Direct)
Footnotes (1)
- The vesting of these performance-based restricted shares was based on the Issuer's attainment of certain performance objectives between 1/1/2023 and 12/31/2025 (the "2023-2025 Performance Period"). Based on the actual level of achievement of such performance objectives for the 2023-2025 Performance Period, the award vested on 3/1/2026 at 100% of the target number of the performance-based restricted shares originally reported by the Reporting Person on 3/2/2023. The time-vesting restrictions on this award of restricted stock will lapse in 1/3 increments on the first, second and third anniversary of the date of grant. The vesting of these performance-based restricted shares is allocated to the Issuer's attainment of the following predetermined performance objectives between 1/1/2026 and 12/31/2028 (the "2026-2028 Performance Period"), as follows: 40% to a Cumulative Same-Store Adjusted EBITDA Growth target; 40% to a Cumulative Same-Store Net Revenue Growth target; and 20% to a Total Shareholder Return ("TSR") Percentile Rank target. The target number (100%) of the total performance-based restricted shares is reported in the table set forth above. Between 0% and 200% of the portion of the target number of performance-based restricted shares allocated to each performance objective will ultimately vest on the third anniversary of the date of grant, subject to the attainment of the applicable performance objective, with the vesting percentage to be determined based upon the level of achievement with respect to the applicable performance objective during the 2026-2028 Performance Period. Vesting occurs in 1/3 increments on the first, second and third anniversary of the date of grant. The vesting of these performance-based restricted shares is subject to the Issuer's attainment of certain performance objectives between 1/1/2024 and 12/31/2026 (the "2024-2026 Performance Period"). The target number (100%) of the total performance-based restricted shares is reported in the table set forth above. Between 0% and 200% of the portion of the target number of performance-based restricted shares allocated to each applicable performance objective will ultimately vest on the third anniversary of the date of grant, subject to the attainment of the applicable performance objective, with the vesting percentage to be determined based upon the level of achievement with respect to the applicable performance objective during the 2024-2026 Performance Period. The vesting of these performance-based restricted shares is subject to the Issuer's attainment of certain performance objectives between 1/1/2025 and 12/31/2027 (the "2025-2027 Performance Period"). The target number (100%) of the total performance-based restricted shares is reported in the table set forth above. Between 0% and 200% of the portion of the target number of performance-based restricted shares allocated to each applicable performance objective will ultimately vest on the third anniversary of the date of grant, subject to the attainment of the applicable performance objective, with the vesting percentage to be determined based upon the level of achievement with respect to the applicable performance objective during the 2025-2027 Performance Period.
FAQ
What equity awards did CYH CFO Jason K. Johnson acquire on March 1, 2026?
Jason K. Johnson received 180,000 performance-based restricted shares and 90,000 stock options on March 1, 2026. He also received 90,000 restricted common shares, with vesting and performance conditions extending across multi-year periods detailed in the filing footnotes.
What are the vesting terms for CYH CFO Jason Johnson’s new restricted stock?
The time-vesting restrictions on Jason Johnson’s new restricted stock lapse in one-third increments on the first, second, and third anniversaries of the grant date. This schedule spreads ownership of the 90,000 restricted common shares over three years, aligning compensation with continued service.